CN113613649A - 用于治疗囊肿状纤维化的化合物及其治疗方法 - Google Patents

用于治疗囊肿状纤维化的化合物及其治疗方法 Download PDF

Info

Publication number
CN113613649A
CN113613649A CN202080018339.8A CN202080018339A CN113613649A CN 113613649 A CN113613649 A CN 113613649A CN 202080018339 A CN202080018339 A CN 202080018339A CN 113613649 A CN113613649 A CN 113613649A
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
compound
room temperature
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080018339.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·P·扎维斯托斯基
C·奥尔曼
F·李
A·科尔德齐
M·莫宁斯塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FLATLEY DISCOVERY LAB
Original Assignee
FLATLEY DISCOVERY LAB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FLATLEY DISCOVERY LAB filed Critical FLATLEY DISCOVERY LAB
Publication of CN113613649A publication Critical patent/CN113613649A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080018339.8A 2019-01-28 2020-01-28 用于治疗囊肿状纤维化的化合物及其治疗方法 Pending CN113613649A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962797743P 2019-01-28 2019-01-28
US62/797,743 2019-01-28
US201962931502P 2019-11-06 2019-11-06
US62/931,502 2019-11-06
PCT/US2020/015441 WO2020160010A1 (en) 2019-01-28 2020-01-28 Compounds and methods for the treatment of cystic fibrosis

Publications (1)

Publication Number Publication Date
CN113613649A true CN113613649A (zh) 2021-11-05

Family

ID=71841934

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080018339.8A Pending CN113613649A (zh) 2019-01-28 2020-01-28 用于治疗囊肿状纤维化的化合物及其治疗方法

Country Status (5)

Country Link
US (1) US20230055237A1 (https=)
EP (1) EP3917516A4 (https=)
JP (1) JP2022518778A (https=)
CN (1) CN113613649A (https=)
WO (1) WO2020160010A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR118050A1 (es) * 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
WO2022032062A1 (en) * 2020-08-06 2022-02-10 Carlex Glass America, Llc Method of attaching a connector to a glazing
EP4029500A1 (en) * 2021-01-15 2022-07-20 Universidad Autónoma de Madrid Tetrahydro-spiroindoline-pyrrolopyrrole-triones inhibitors of the nrf2-beta-trcp interaction for use in the treatment of nrf2-related diseases
RU2763141C1 (ru) * 2021-06-29 2021-12-27 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Этил (3r*,3a'r*,8a'r*,8b's*)-1',2,3'-триоксо-2',5-дифенил-1-(4-хлорфенил)-1,2,2',3',3a',6',7',8',8a',8b'-декагидро-1'h-спиро[пиррол-3,4'-пирроло[3,4-a]пирролизин]-4-карбоксилат, обладающий противомикробной активностью

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100130506A1 (en) * 2007-12-10 2010-05-27 Novartis Ag Organic Compounds
WO2016201440A1 (en) * 2015-06-12 2016-12-15 The Regents Of The University Of California Spiroindolinones and therapeutic uses thereof
US20170204110A1 (en) * 2015-12-30 2017-07-20 Flatley Discovery Lab, Llc Compounds and methods for the treatment of cystic fibrosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100130506A1 (en) * 2007-12-10 2010-05-27 Novartis Ag Organic Compounds
WO2016201440A1 (en) * 2015-06-12 2016-12-15 The Regents Of The University Of California Spiroindolinones and therapeutic uses thereof
US20170204110A1 (en) * 2015-12-30 2017-07-20 Flatley Discovery Lab, Llc Compounds and methods for the treatment of cystic fibrosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIE YONG-MEI等: "Facile Synthesis of FunctionalizedSpiropyrrolizidine Oxindoles via a Three-Component Tandem CycloadditionReaction", 《MOLECULES》, vol. 16, no. 10, 31 October 2011 (2011-10-31), pages 17 - 18 *

Also Published As

Publication number Publication date
JP2022518778A (ja) 2022-03-16
EP3917516A4 (en) 2022-10-12
US20230055237A1 (en) 2023-02-23
WO2020160010A1 (en) 2020-08-06
EP3917516A1 (en) 2021-12-08

Similar Documents

Publication Publication Date Title
CN116783204B (zh) 囊性纤维化跨膜传导调控因子的调节剂
CN107849013B (zh) 作为dub抑制剂用于治疗癌症的氰基吡咯烷类
CN112566916B (zh) 作为pad4抑制剂的经取代的噻吩并吡咯
CN113613649A (zh) 用于治疗囊肿状纤维化的化合物及其治疗方法
CN112996791A (zh) 抗乙型肝炎病毒HBV的6,7-二氢-4H-吡唑并[1,5-a]吡嗪吲哚-2-甲酰胺活性剂
CN116670143A (zh) 囊性纤维化跨膜传导调控因子的调节剂
CN107207487A (zh) 用于提高cftr活性的化合物、组合物和方法
CN112771027A (zh) 溶血磷脂酸受体拮抗剂及其制备方法
CN107074852A (zh) ROR‑γ的二氢吡咯并吡啶抑制剂
WO2015124063A1 (zh) 丙肝病毒抑制剂及其制药用途
WO2018121678A1 (zh) 一种抗病毒核苷类似物前药及其组合物、用途
CN114599648A (zh) 作为lpa拮抗剂的三唑羧酸
WO2022165513A1 (en) Cdk2 inhibitors and methods of using the same
EP4364804A2 (en) Inhibitors of keap1-nrf2 protein-protein interaction
CN112789087A (zh) Pad酶的苯并咪唑抑制剂
CN107001316A (zh) 作为抗菌剂的喹诺酮衍生物
WO2023006013A1 (zh) 新型parp7抑制剂及其应用
WO2023232130A1 (zh) 一种杂环化合物ccr4抑制剂及其用途
CN104650070B (zh) 二氢嘧啶类化合物及其在药物中的应用
WO2023141852A1 (zh) Cdk2抑制剂及其制备方法和用途
CN116157392A (zh) 靶向rna结合蛋白或rna修饰蛋白的化合物
CN105399698B (zh) 芳杂环类衍生物及其在药物中的应用
CN114127082A (zh) 作为sting调节剂的经修饰的环状二核苷化合物
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
CN114007695A (zh) 作为am2受体抑制剂的杂环螺-化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211105

WD01 Invention patent application deemed withdrawn after publication